Navigation Links
Development of more muscular trout could boost commercial aquaculture
Date:3/10/2010

KINGSTON, R.I. March 10, 2010 A 10-year effort by a University of Rhode Island scientist to develop transgenic rainbow trout with enhanced muscle growth has yielded fish with what have been described as six-pack abs and muscular shoulders that could provide a boost to the commercial aquaculture industry.

Terry Bradley, a URI professor of fisheries and aquaculture, said his research into the inhibition of myostatin, a protein that slows muscle growth, has obtained "stunning results" in the last two years, with trout growing 15 to 20 percent more muscle mass than standard fish.

"Belgian blue cattle have a natural mutation in myostatin causing a 20 to 25 percent increase in muscle mass, and mice overexpressing myostatin exhibit a two-fold increase in skeletal muscle mass. But fish have a very different mechanism of muscle growth than mammals, so we weren't certain it was going to work," Bradley said.

According to Bradley, the number of muscle fibers in mammals is limited after birth, but in fish, muscle fiber numbers increase throughout their lifespan. Since inhibition of myostatin increases the numbers of muscle fibers, it had been a mystery as to whether inhibiting myostatin would cause an increase in muscle growth in fish.

Bradley and a team of graduate students spent 500 hours injecting 20,000 rainbow trout eggs with various DNA types designed to inhibit myostatin. Of the eggs that hatched, 300 carried the gene that led to increased muscle growth. After two years, most exhibited a "six-pack ab" effect, even though fish lack standard abdominal muscles. They also have increased musculature throughout, including a prominent dorsal hump that made them look like they had muscular shoulders.

The first generation of transgenic trout were subsequently spawned, and offspring carrying the gene in all of their muscle cells have been produced. Studies are under way to determine if the fish grow at a faster rate as well.

"Our findings are quite stunning," said Bradley, who also studies salmon, flounder and tuna. "The results have significant implications for commercial aquaculture and provide completely novel information on the mechanisms of fish growth. The results also allow for comparisons between the mechanisms of growth of muscle in mammals versus fish, and it could shed light on muscle wasting diseases in humans."

About 500,000 metric tons of rainbow trout are raised each year in aquaculture facilities in the United States and Europe. In the U.S., some 1,000 trout farms produce approximately $80 million of trout annually, mostly in Idaho, New York, Pennsylvania and California. Assuming Bradley's transgenic fish meet with regulatory approval, it could provide a boost to the industry by enabling aquaculturists to grow larger fish without increasing the amount of food the fish are fed.

"One of the advantages of this approach is that the modified genes introduced into the fish use the same mechanism and cause the same type of effect that occurs naturally in Belgian blue cattle and other 'double muscled' animals," said Bradley.

While the transgenic trout may look like bodybuilders, Bradley said they exhibit normal behaviors. He will continue to study the fish to learn if the new gene affects any other genes, and to determine if new husbandry practices will aid in the raising of the trout.


'/>"/>

Contact: Todd McLeish
tmcleish@uri.edu
401-874-7892
University of Rhode Island
Source:Eurekalert

Related biology news :

1. Sonic hedgehog gene found in an unexpected place during limb development
2. Model may offer better understanding of embryonic development
3. Chemical competition: Research identifies new mechanism regulating embryonic development
4. ACS webinar features developments in online water and wastewater monitoring
5. Rondaxe and TD2 form strategic drug development alliance
6. Zebrafish swim into drug development
7. Kentucky study advances new target for CNS drug development
8. In early heart development, genes work in tandem
9. Conservation areas threatened nationally by housing development
10. Enzyme necessary for development of healthy immune system
11. Biogen Idecs oral compound BG-12 achieves development milestones in MS and RA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... 28, 2017 Sangamo Therapeutics, Inc. (NASDAQ: ... reported its fourth quarter and full year 2016 ... this year we rebranded our company as Sangamo ... genomic therapies using our industry leading platform technologies ... cell therapy," said Sandy Macrae , CEO ...
(Date:2/28/2017)... , February 28, 2017 The ... for assessment are the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ... AUPH ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... companies belong to the Healthcare sector, which was narrowly mixed ... Health Care Index declining less than 0.1%, while shares of ...
(Date:2/27/2017)... , February 27, 2017 A Europe-wide ... indicated that researchers using animals in their research treat them with ... 26 countries, and detailed analysis of the results indicates that there ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... CITY, Calif. , Feb. 27, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced today the U.S. Food and ... Drug Application (NDA) under section 505(b)(2) for DSUVIA™ ... the treatment of patients with moderate-to-severe acute pain ...
Breaking Biology Technology: